Executive readout · one minute
Call research workspace
Read the call alongside every captured source. 8-K earnings release, 10-K stay in one workspace.
GANX
$1.79
+1.14%
GANX
· Gain Therapeutics, Inc.
$1.79
+0.02 (+1.14%)
At close · Sep 2
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our projected cash outflows for the upcoming periods raise substantial doubt about our ability to continue as a going concern for at least 12 months from the issuance of the financial statements included elsewhere in this Quarterly Report. We will need to raise additional capital to fund continued operations beyond the second quarter of 2027.”View the 10-Q filed Aug 11, 2026
Market Cap
$77.90M
Shares
43.64M
All earnings calls
Earnings call · FY2025 Q4
Gain Therapeutics, Inc. (GANX) Q4 2025 Earnings Call
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Net income · derived Q4
-$4.54M
Research materials
Open the source you need; every reader stays inside this workspace.
SEC filing · Item 2.02
8-K earnings release
Filed Mar 26, 2026 · complete as-filed document
SEC periodic report
10-K report
Filed Mar 26, 2026 · complete as-filed document